Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Duchenne muscular dystrophy (DMD)
Biotech
FDA rebuffs Entrada's attempt to get DMD clinical hold lifted
Entrada has failed to persuade the FDA to lift the nearly yearlong clinical hold on its leading DMD candidate despite submitting more information.
James Waldron
Nov 22, 2023 9:25am
Vertex drops lung therapy, rethinks DMD drug's path to clinic
Nov 7, 2023 6:00am
PTC deepens layoffs as DMD drug faces loss of EU authorization
Sep 29, 2023 8:51am
FibroGen fails in DMD, continuing rotten run of phase 3 flops
Aug 30, 2023 5:54am
Lilly's Prevail drops deal value for Precision gene therapy pact
Jul 7, 2023 10:30am
Another clinical failure sends FibroGen hunting for cost savings
Jun 26, 2023 9:42am